
21st Annual bioProcessUK Conference 2024

GyaniMed

A generative AI for scientists workspace

By Intelligence

"Creating a universally accessible AI workspace for drug development, breaking down barriers to accelerate knowledge transfer and foster sustainability in medicine manufacturing."



Team



Swapnil Khadke, PhD

CEO

TechBio R&D leader Drug delivery innovator, CMC expert.



Lonza



Neil Robertson

CTO

Lead Software Engineer Full-Stack / Python developer. AI/LLM innovator.

> JPMORGAN Chase & Co.



Dennis Christensen, PhD

Scientific Advisor

Head of R&D, Croda Vaccine formulation leader, 18-year immunology and adjuvant expert.

CRODA



Chris Rushworth

Product Advisor

Product Strategy & Client Executive Digital transformation leader, healthcare expert.

Q Palantir



Priya Kalia, PhD

Communications Advisor

20-year strategic comms leader, science, tech, environment expert.



The problem

"The pharmaceutical analytics market is projected to grow to \$102 billion by 2030, yet most solutions fail to integrate production and research data effectively."



Expert Opinion:

"Our current Electronic Lab Notebooks are difficult to customize and inefficient. Even creating a simple database from a CSV file can be challenging due to the complexity of the associated processes."

- User at a CRO. UK

Disconnected Data Systems

Scattered, incompatible tools hinder collaboration, making it difficult to leverage insights across teams

Al Gap in Late-Stage Drug Development

While AI has revolutionized early discovery, mid-to-late-stage development remains siloed, leaving teams overwhelmed by fragmented data.


Sustainability Overlooked

Inefficient workflows lead to resource wastage, redundant experiments, and higher carbon footprints, making the industry unsustainable.

Connections in Data


is essential for digital transformation is the missing link for intelligence and innovation

Organizations are drowning in data but data is fragmented and getting insights is harder



Source: https://arxiv.org/abs/2403.11996

The solution



Transforming manufacturing data into actionable insights to streamline sustainable drug manufacturing

First step is - get your data AI ready!

Features

- Al-Ready Knowledge Databases: Automatically transforms messy lab data into a unified, Al-ready format.
- Integrated Research and Production: Bridges experimental research with manufacturing for seamless workflows.
- Synthetic Data Generation:
 Produces high-fidelity
 synthetic data to enhance
 predictive modelling and
 support decision-making.
- Natural Language Interface: Empowers scientists to query and analyse complex datasets using easy natural language questions.

Benefits

- Accelerated Decision-Making: Facilitates datadriven decisions across all stages of drug development.
- Enhanced Collaboration: Breaks down data silos, reducing cross-team data retrieval times.
- Faster Time-to-Market:
 Shortens drug development timelines by months, delivering life-saving treatments sooner.
- Actionable Insights: Provides tailored recommendations, improving research accuracy and efficiency.

How it works

GyaniMed™

by Intelligence 🛞

1. Ingest and Unify Data

Automatically clean, ingest, and structure lab and machine data.

2. Build Knowledge Graphs


Generate Al-ready graphs for seamless insights and workflow integration.

3. Data validation with Al

Enable predictive modelling and actionable insights using natural language interfaces.

Knowledge Integration Pipeline

IntelligenceQ™



Traction

Projects



Startup Programmes



Memberships











MVP Developed: Secure Offline Al Workspace for Scientists (Aug 2024)

We have developed a fully offline AI workspace that runs **entirely without internet** on a regular PC, ensuring cybersecurity and data privacy. It integrates locally owned **AI models** and allows users to build and query graph databases using natural language.



Value Proposition Study with CPI (Sept-Dec 2024)

We have partnered with the **Centre for Process Innovation (CPI)** for a proof-of-concept, funded by **Innovate UK Business Growth**. The focus is on validating customer pain-points, data security, scalability, and user experience.



Industry Partnerships (Jan 2025)

We are writing a project with Croda on Re-purposing of old data to generate new vaccines, starting in Jan 2025.

Market Analysis



Total Addressable Market (TAM)

Pharmaceutical, biotech, clinical organisations

- Contract Research Organizations (CROs)
- CDMOs
- Universities

Our target users



Service Addressable Market (SAM) 15%

SOM **◄** \$1.5 bn



Target Market (10%)

Our current focus is biologicals and high-value medicines.

Market Share: \$30 M



Market Share

2% adoption rate

Revenue model

Enterprise Partnerships

Large-scale software installations for major clients, with contracts valued at approximately **£50-100k each**. Based on current demand, we are targeting 2-3 contracts annually.

Marketplace Licensing

Subscription-based SaaS model (£50-£650/ users/month) on Snowflake and Google Marketplace, offering scalable, recurring revenue with unique proprietary AI solutions for medicine manufacturing.

Consortium Collaborations

and academic

partnerships to codevelop solutions,
funded by grants that
secure ongoing research
and public impact
projects, driving future
opportunities for
innovation.

Competition

Company	Focus Area	Key Limitations	IntelligenceQ's Advantage
Benchling	Data Management & Collaboration	Lacks integration beyond data storage, siloed use	Full-cycle data integration for seamless workflows
Dotmatics	Research Data Management	Limited to isolated data tools, no Al-driven insights	End-to-end AI insights for accelerated development
Synthace	R&D Automation and Process Design	Focused on automation, lacks cross-phase optimization	Predictive modeling and holistic optimization
Palantir	Data Integration and Analytics	Generic analytics, not tailored for drug development	Al tailored to drug R&D, reducing time and cost

Investment Overview

Raising

£500k

Offering [SEIS/EIS] tax deductions

SEIS/EIS Advance Assurance available (for UK investors only)

Stage: Pre-revenue

Target: Close: Jan 25

Round: Discounted Seed FAST

£50,000

Minimum investment amount

Offering standard investor protections:

Drag along, tag along and pre-emption rights

We're using <u>SeedLegals</u> to easily negotiate, sign and store investment documents.

Click here for more details...

https://app.seedlegals.com/pitch/c XNBza5xGKb/IntelligenceQ

Thank you.

Q&A





















Appendix














Gyan


(Sanskrit: ज्ञान) Knowledge; information, understanding, or skill that you get from experience or education.

Med


(short for **Medical**) Pertaining to the science or practice of medicine; relating to the maintenance of health.









GyaniMed AI: Generative AI workspace for late-stage drug development




User story




Integration Layers



GyaniMed Recursive Al Agentic Workflow for Data Model Building



GyaniMed Vision: Analysing scientific plots extracting accurate interpretation



GyaniMed Scientist-in-the-loop for accurate schema generation and to control Al models

